Effects of Antibodies to White Blood Cells on Platelet Transfusion Patients
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/6/2019 |
| Start Date: | April 10, 2007 |
| End Date: | August 10, 2012 |
Pilot Study of the Incidence of HLA Class I and Class II Antibodies in Platelet Donors and Their Effects on the Transfusion Recipient
This study will determine if transfusion of platelets containing HLA antibodies (certain
antibodies to white blood cells) are more likely to cause transfusion reactions than
transfusion of platelets that do not contain HLA antibodies.
People 18 years of age or older who donate platelets at the NIH Clinical Center may be
eligible for this study.
An extra tube of blood (about one teaspoon) is obtained from participating donors at the time
of their donation at the NIH Platelet Center. The blood plasma in the extra tube is tested
for HLA antibodies and antibodies to certain white blood cells called granulocytes. The
research sample is assigned a code number for identification and sent to the HLA Laboratory
in the Department of Transfusion Medicine.
antibodies to white blood cells) are more likely to cause transfusion reactions than
transfusion of platelets that do not contain HLA antibodies.
People 18 years of age or older who donate platelets at the NIH Clinical Center may be
eligible for this study.
An extra tube of blood (about one teaspoon) is obtained from participating donors at the time
of their donation at the NIH Platelet Center. The blood plasma in the extra tube is tested
for HLA antibodies and antibodies to certain white blood cells called granulocytes. The
research sample is assigned a code number for identification and sent to the HLA Laboratory
in the Department of Transfusion Medicine.
Leukocyte antibodies can cause febrile transfusion reactions, pulmonary reactions to
granulocyte transfusions, and transfusion related acute lung injury (TRALI). Despite the fact
that the role of leukocyte antibodies in these reactions was first described almost 50 years
ago, and that TRALI is now the leading cause of transfusion related fatalities, much remains
uncertain concerning the role of HLA antibodies in these reactions. The primary purpose of
this study is to retrospectively and prospectively determine if the incidence and nature of
transfusion reactions differs in Clinical Center (CC) patients that were transfused with
platelet components from donors with HLA antibodies and those without HLA antibodies. In
addition, this study will prospectively determine the incidence of HLA antibodies in the NIH
Department of Transfusion Medicine (DTM) platelet donor population. In this natural history
study a 10-mL blood sample will be drawn from 600 platelet donors at the time that they are
in the DTM donating platelets and it will be tested for HLA antibodies in the DTM. The blood
sample for HLA antibody testing will be collected with other samples collected as part of the
regular platelet donation process. Reactions in platelet transfusion recipients will be
assessed by reviewing CC and DTM patient records.
granulocyte transfusions, and transfusion related acute lung injury (TRALI). Despite the fact
that the role of leukocyte antibodies in these reactions was first described almost 50 years
ago, and that TRALI is now the leading cause of transfusion related fatalities, much remains
uncertain concerning the role of HLA antibodies in these reactions. The primary purpose of
this study is to retrospectively and prospectively determine if the incidence and nature of
transfusion reactions differs in Clinical Center (CC) patients that were transfused with
platelet components from donors with HLA antibodies and those without HLA antibodies. In
addition, this study will prospectively determine the incidence of HLA antibodies in the NIH
Department of Transfusion Medicine (DTM) platelet donor population. In this natural history
study a 10-mL blood sample will be drawn from 600 platelet donors at the time that they are
in the DTM donating platelets and it will be tested for HLA antibodies in the DTM. The blood
sample for HLA antibody testing will be collected with other samples collected as part of the
regular platelet donation process. Reactions in platelet transfusion recipients will be
assessed by reviewing CC and DTM patient records.
- INCLUSION CRITERIA:
1. Both male and female donors
2. Any ethnic group
3. 18 years of age or older
4. Must meet the criteria for donating platelets in the DTM
EXCLUSION CRITERIA:
1. Donors are not eligible to donate platelets in the DTM
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
